Revolution Medicines, Inc. Stock Price, News & Analysis

Revolution Medicines (Nasdaq: RVMD) announced that CEO Mark A. Goldsmith will present at the 39th Annual J.P. Morgan Healthcare Conference from January 11-14, 2021. During the presentation, scheduled for January 12 at 5:20 p.m. Eastern, Dr. Goldsmith will discuss the advancement of two first-in-class RAS(ON) Inhibitor programs into IND-enabling development. He will also provide updates on three RAS Companion Inhibitors: RMC-4630, RMC-5552, and the newly introduced RMC-5845. The presentation will be available via webcast on the company's website.

Revolution Medicines (RVMD) provided an update on its RMC-4630 programs for RAS-addicted cancers, announcing selected Phase 2 doses for both monotherapy and combination therapies. Financial results for Q3 2020 show revenue of $12.7 million, up from $12.5 million in Q3 2019. However, R&D expenses rose to $34.9 million, leading to a net loss of $27.2 million, compared to a loss of $12.8 million in the previous year. The company has positioned itself as a leader in RAS-targeted therapies and has extended its clinical collaborations to enhance its drug development pipeline.

Revolution Medicines (RVMD) recently presented interim data from its Phase 1b/2 trial of RMC-4630 combined with cobimetinib at the EORTC-NCI-AACR Symposium. The dual intermittent dosing strategy showed tolerable adverse effects and exceeded target plasma exposures, indicating potential clinical activity in KRAS-mutated colorectal cancers. Additionally, a new collaboration with AstraZeneca aims to explore RMC-4630's combination with a KRAS-targeting drug. Preliminary results suggest anti-tumor activity, with tumor volume reduction in three of seven patients receiving the highest dose.

Revolution Medicines, Inc. (NASDAQ: RVMD) announced that interim data from its Phase 1b/2 trial, RMC-4630-02, will be presented at the EORTC-NCI-AACR 32nd Symposium on October 24-25, 2020. This trial evaluates the safety and efficacy of RMC-4630 in combination with cobimetinib for patients with relapsed/refractory solid tumors. The company aims to explore drug combinations as a strategy to overcome resistance mechanisms in RAS-addicted cancers. The presentation will focus on dosing regimens and pharmacokinetic findings.

Revolution Medicines (Nasdaq: RVMD) presented groundbreaking data on its KRAS^G12D(ON) inhibitors, showcasing their ability to induce tumor regressions in a preclinical human pancreatic cancer model. This marks the first public demonstration of anti-tumor activity for these inhibitors, emphasizing their potential in treating cancers associated with the KRAS^G12D mutation, which is significant given the lack of approved therapies targeting this mutation. The KRAS^G12D(ON) program is entering lead optimization after showing effective dose-dependent anti-tumor results.

Revolution Medicines, Inc. (Nasdaq: RVMD) announced that CEO Mark A. Goldsmith will present at the H.C. Wainwright 22nd Annual Global Investment Conference from September 14-16, 2020. His presentation is scheduled for September 14 at 11:00 a.m. Eastern Time. A live webcast will be accessible through the company's website, with a replay available post-conference. Revolution Medicines focuses on precision oncology, developing targeted therapies for RAS-addicted cancers, including RMC-4630 and RMC-5552, aimed at inhibiting critical cancer signaling pathways.

Revolution Medicines (Nasdaq: RVMD) will participate in the 2^nd Annual RAS-Targeted Drug Development Conference from September 14-16, 2020. Key presentations include:

• Title: Approaches to Inhibiting RAS Driven Tumors Beyond KRAS G12C
  Presenter: Steve Kelsey, M.D.
  Date: September 16, 2020, 9:00 a.m. Eastern
• Title: Empowering Combination Strategies to Target RAS Mutant Cancers
  Participant: Jan Smith, Ph.D.
  Date: September 16, 2020, 4:30 p.m. Eastern
• Workshop: Navigating the Future Potential of Combination Strategies
  Co-Leader: Jan Smith, Ph.D.
  Date: September 14, 2020, 11:30 a.m. Eastern

Revolution Medicines (Nasdaq: RVMD) announced the closing of a public offering of 6,900,000 shares at $26.00 each, generating gross proceeds of $179.4 million before deductions. The offering included 900,000 additional shares purchased by underwriters. The funds are expected to support the company’s focus on developing targeted cancer therapies, specifically those targeting RAS and mTOR pathways. J.P. Morgan, Cowen, SVB Leerink, and Guggenheim Securities managed the offering.

Revolution Medicines has announced a public offering of 6,000,000 shares of common stock at a price of $26.00 per share, aiming to raise approximately $156 million before expenses. The offering includes an option for underwriters to purchase up to 900,000 additional shares. The offering is set to close on July 13, 2020, subject to standard closing conditions. Notable financial institutions involved include J.P. Morgan, Cowen, SVB Leerink, and Guggenheim Securities.